Thalidomide - a chance for use in modern disease treatment?
Authors:
- Marta TurekMTMarta Turek
- Julia SzlążekJSJulia Szlążek
- Michalina ZagalskaMZMichalina Zagalska
- Adam Jan ZąbekAZAdam Jan Ząbek
- Jakub Paweł KuźniarJKJakub Paweł Kuźniar
- Emilia Gabriela ChrzanowskaECEmilia Gabriela Chrzanowska
- Tomasz TamborskiTTTomasz Tamborski
- Adam GrzebinogaAGAdam Grzebinoga
- Barbara RoguskaBRBarbara Roguska
Open Access
- 7 May 2025
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 81, 59794
Abstract
Thalidomide, despite its controversial history associated with teratogenic effects is currently used in the treatment of various conditions including oncological, immunological and dermatological diseases. The drug exhibits anti-inflammatory, immunomodulatory and anti-angiogenic effects, making it potentially effective in the treatment of various diseases. The mechanism of action is based on modulating the CRL4CRBN E3 ubiquitin ligase complex by binding to cereblon (CRBN), which leads to a change in the substrates recognized by this complex and the degradation of specific proteins. Thalidomide is used in the treatment of multiple myeloma, especially in cases resistant to other treatment methods. In addition, it can support the treatment of glioblastoma multiforme due to its anti-angiogenic and immunomodulatory effects. It is also used in the treatment of Crohn's disease, systemic lupus erythematosus, and idiopathic pulmonary fibrosis (IPF). In Crohn's disease it works by blocking TNF-α and modulating the immune response. In cutaneous lupus erythematosus it reduces inflammation, modulates the immune response and inhibits angiogenesis. In IPF, it inhibits the production of pro-inflammatory cytokines and reduces oxidative stress. The use of thalidomide is associated with a risk of teratogenicity, which requires strict control and the use of effective methods of contraception. In addition thalidomide can cause side effects, mainly hematological and gastrointestinal disorders. Due to the side effect profile, the use of thalidomide requires caution and close monitoring of the patient by a physician.Keywords
This publication has 22 references indexed in Scilit:
- Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trialsJournal of Neuro-Oncology, 2024
- Thalidomide: History of Research and Perspectives for Its Medical Use (Review)Pharmaceutical Chemistry Journal, 2024
- Thalidomide interaction with inflammation in idiopathic pulmonary fibrosisInflammopharmacology, 2023
- The efficacy and safety of thalidomide in the treatment of refractory Crohn's disease in adults: a double-center, double-blind, randomized–controlled trialGastroenterology Report, 2022
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2022
- Repurposing of thalidomide and its derivatives for the treatment of SARS‐coV‐2 infections: Hints on molecular actionBritish Journal of Clinical Pharmacology, 2021
- Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series studyInternational Journal of Infectious Diseases, 2021
- Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermediaAnnals of Hematology, 2018
- Thalidomide‐induced teratogenesis: History and mechanismsBirth Defects Research Part C: Embryo Today: Reviews, 2015
- Thalidomide: new indications?Joint Bone Spine, 2001